Dosimetry of particle radiotherapy for liver cancer adjacent to gastrointestinal tract
Wang Weiwei, Sun Jiayao, Wang Zheng, Sheng Yinxiangzi, Jiang Guoliang, Kambiz Shahnazi
Department of Medical Physics,Shanghai Proton and Heavy Ion Center,Shanghai 201321,China (Wang WW,Sun JY,Sheng YXZ, Shahnazi K);Department of Radiation Oncology,Shanghai Proton and Heavy Ion Center,Shanghai 201321,China (Wang Z,Jiang GL)
Abstract：Objective To investigate the dosimetric advantages of proton and heavy ion radiotherapy (particle radiotherapy) for liver cancer adjacent to gastrointestinal tract. Methods Ten patients with liver cancer adjacent to gastrointestinal tract receiving radiotherapy were recruited in this study. The prescription was first given with 50 Gy (RBE)/25 fractions to planning target volume 1(PTV-1) using proton irradiation,and then administered with 15 Gy (RBE)/5 fractions to PTV-2 using carbon-ion irradiation. A simultaneous integrated boost regime was established using the same variables and prescription. The organ at risk (OAR) constraints were referred to RTOG 1201.All plans were performed for dose evaluation after qualifying the OAR constraints. Results The dose coverage of 95% of the prescribed dose(V95) for PTV-1 from the photon plan (97.15%±4.27%),slightly better than (96.25±6.69%) from the particle plan (P=0.049).The V95 of PTV-2 from the particle plan was (94.6%±6.22%),comparable to (95.12%±3.49%) from the photon plan (P=0.277).The integral dose of Body-PTV-1 delivered by the particle plan was merely 39.9% of that delivered by the photon plan. The mean liver-GTV dose from the particle plan was only 81.8% of that from the photon plan. The low-dose irradiation to the stomach and duodenum from the particle plan was significantly lower than that from the photon plan. Conclusions The dose to the liver-gross tumor volume (GTV) is the main factor limiting the increase of total dose to the tumors. When the absolute GTV in the liver is relatively large,particle radiotherapy can maintain comparable dose coverage to the tumors as the photon radiotherapy whereas significantly reduce the dose to the liver-GTV.
Wang Weiwei,Sun Jiayao,Wang Zheng et al. Dosimetry of particle radiotherapy for liver cancer adjacent to gastrointestinal tract[J]. Chinese Journal of Radiation Oncology, 2018, 27(11): 999-1003.
[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer,2015,136(5):E359-E386.DOI:10.1002/ijc.29210. [2] Chen W,Zheng R,Zhang S,et al. Report of cancer incidence and mortality in China,2010[J].Ann Translat Med,2014,2(7):61. DOI:10.3978/j.issn.2305-5839.2014.04.05. [3] 贺立山,翁孝刚.内科学[M].6版.北京:人民卫生出版社,2005. He LS, Weng XG. Internal medicine:the sixth edition[M]. 6 ed. Beijing:People′s medical publishing house,2005. [4] 吕桂帅,陈磊,王红阳.我国肝癌研究的现状与前景[J].生命科学,2015(3):237-248.DOI:10.13376/j.cbls/2015034. Lyu GS,Chen L, Wang HY. Research progress and prospect of liver cancer in China[J].Chin Bull Life Sci, 2015(3):237-248.DOI:10.13376/j.cbls/2015034. [5] 罗政,饶建,殷蔚伯.放疗在原发性肝癌治疗中地位和现状[J].中华放射肿瘤学杂志,2006,15(4):345-346.DOI:10.3760/j.issn:1004-4221.2006.04.033. Luo Z, Rao J, Yin WB. The status and position of radiotherapy in the treatment of primary liver cancer[J].Chin J Radit Oncol,2006,15(4):345-346.DOI:10.3760/j.issn:1004-4221.2006.04.033. [6] Zeng Z C,Jiang G L,Wang G M,et al. DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line[J].World J Gastroenterol,2002,8(5):797-803.DOI:10.3748/wjg.v8.i5.797. [7] Sugahara S,Oshiro Y,Nakayama H,et al. Proton beam therapy for large hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys,2010,76(2):460-466.DOI:10.1016/j.ijrobp.2009.02.030. [8] Kato H,Tsujii H,Miyamoto T,et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis[J].Int J Radiat Oncol Biol Phys,2004,59(5):1468-1476.DOI:10.1016/j.ijrobp.2004.01.032. [9] Vedam SS,Keall PJ,Kini V R,et al. Acquiring a four-dimensional computed tomography dataset using an external respiratory signal[J].Phys Med Biol,2003,48(1):45.DOI:10.1088/0031-9155/48/1/304. [10] Schneider U,Pedroni E,Lomax A.The calibration of CT Hounsfield units for radiotherapy treatment planning[J].Phys Med Biol,1996,41(1):111-124. DOI:10.1088/0031-9155/41/1/009. [11] Paganetti H.Range uncertainties in proton therapy and the role of Monte Carlo simulations[J].Phys Med Biol,2012,57(11):99-117.DOI:10.1088/0031-9155/57/11/R99. [12] Kramer M,Scholz M.Treatment planning for heavy-ion radiotherapy:calculation and optimization of biologically effective dose[J].Phys Med Biol,2000,45(11):3319-3330. DOI:10.1088/0031-9155/45/11/314.
2018, Vol. 27 
